Blueprint medicines7/28/2023 ![]() Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. ANGN witnessed an earnings surprise of 66.42% on average. Loss per share estimates for Angion Biomedica have narrowed 6.1% for 2022 and 3.9% for 2023 in the past 60 days.Įarnings of Angion Biomedica surpassed estimates in three of the trailing four quarters and missed the mark on the other occasion. IMCR witnessed an earnings surprise of 68.34% on average. Loss per share estimates for Immunocore have narrowed 39.7% for 2022 and 39.4% for 2023 in the past 60 days.Įarnings of Immunocore surpassed estimates in three of the trailing four quarters and missed the same on the remaining occasion. SNDX witnessed an earnings surprise of 95.39% on average Loss per share estimates for Syndax Pharmaceuticals have narrowed 4.9% for 2022 and 10.1% for 2023 in the past 60 days.Įarnings of Syndax Pharmaceuticals surpassed estimates in three of the trailing four quarters and met the same on the other occasion. Shares of Blueprint Medicines have plunged 59.4% so far this year compared with the industry’s decline of 19.9%. The FDA has granted breakthrough therapy designation to Ayvakit for the treatment of moderate-to-severe indolent SM. Data from the same showed that treatment with Ayvakit led to clinically meaningful and highly significant improvements across the primary and all key secondary endpoints, including patient-reported symptoms and measures of mast cell burden.Īyvakit had a favorable safety profile compared to the control arm. In August 2022, BPMC announced top-line data from part 2 of the PIONEER study, which evaluated Ayvakit for treating indolent SM. The sNDA was based on data from the registrational PIONEER study, which evaluated Ayvakit for the treatment of indolent SM. This marks the first regulatory submission for the given indication. The company is seeking approval for Ayvakit for the treatment of adults with indolent systemic mastocytosis (SM), a rare disease. Blueprint Medicines Corporation BPMC announced that it has submitted a supplemental new drug application to the FDA seeking label expansion of its lead drug, Ayvakit (avapritinib) for a new indication.
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |